Enterprise Value to EBITDA Ratio: Halozyme Therapeutics (HALO)

halozyme.com (HALO) - corporate logo

The historical EV/EBITDA dynamics of Halozyme Therapeutics (HALO) demonstrate the efficiency of the high-margin ENHANZE licensing model. Growth in these metrics is supported by outsourcing development through CROs and CMOs, which eliminates plant expenditures. However, monitoring patents through 2030 remains a critical factor. The current value of 11.72 sets the current magnitude of the metric, allowing for an objective assessment of the business value relative to earnings.

HALO Halozyme Therapeutics, Inc.: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/15/2026

Comprehensive metric breakdowns and analytics for Halozyme (HALO)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Fundamental company analysis:HALO (Halozyme Therapeutics)
Product sample of halozyme.com

Investors utilize comprehensive metrics to verify the fair value of the issuer while accounting for debt load. The current EV/EBITDA multiple relates the total enterprise value to operating profit before interest, taxes, depreciation, and amortization. For Halozyme Therapeutics (HALO), this indicator demonstrates the efficiency of ENHANZE license monetization relative to market capitalization. The decline of this metric on the chart signals that the company's assets are undervalued amid rising marginal royalties.

Who Halozyme Therapeutics competes with

BeiGene Oncology - Enterprise Value to EBITDA Ratio|RVMD - Enterprise Value to EBITDA Ratio|AAPG: Enterprise Value to EBITDA Ratio|CGON - EV/EBITDA Multiple|UroGen (URGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Bicara Bio - Business Value to Operating Income Before Depreciation|PSNL (Personalis Inc) - EV/EBITDA Multiple|Company Value to EBITDA Erasca, Inc. ERAS|EV/EBITDA Multiple DCTH|YMAB - Company Value to EBITDA|Aura Biosciences Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Candel Therapeutics CADL|accuray.com - EV/EBITDA Multiple|SLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU (actuatetherapeutics.com) - Enterprise Value to EBITDA Ratio|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tuhurabio.com|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple